RBC Capital on Perspective Therapeutics (CATX): 'We see significant upside potential for investors with patience'

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $14.00 price target on Perspective Therapeutics Inc (NYSE: CATX).

The analyst commented: "Alpha Emitter Readouts To Mature Over 2H26; Today CATX reported their 1Q26 earnings and we caught up with the team. We expect CATX to wait to release additional VMT-α-NET efficacy data until it is fully mature later in the year - which may mean that the upcoming ASCO update could be more focused on underscoring the continuing clean safety profile of the treatment; meanwhile other programs remain on track for 2H26 updates. Even with the recent weakness and some delays in seeing full efficacy data, we think shares are meaningfully undervaluing the opportunity in NETs given the solid efficacy paired with best-in-class safety, and we see significant upside potential for investors with the patience to see the data through."

For an analyst ratings summary and ratings history on Perspective Therapeutics Inc click here. For more ratings news on Perspective Therapeutics Inc click here.

Shares of Perspective Therapeutics Inc closed at $3.88 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Reading (RDI) Tops Q2 EPS by 4c